Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure
Journal of the American Heart Association
DECEMBER 1, 2023
BackgroundAn increased risk of recurrent stroke is noted in patients with atrial fibrillation despite direct oral anticoagulant (DOAC) use. 0.45] for rivaroxaban), and a 69% to 83% reduced risk of net composite outcomes (aHR, 0.25 [95% CI, 0.18–0.35] We identified 3759 patients with DOAC failure. 0.41] for rivaroxaban).ConclusionsIn
Let's personalize your content